25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

PTCT (PTC Therapeutics Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze PTC Therapeutics Inc together

I guess you are interested in PTC Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – PTC Therapeutics Inc’s Financial Insights
  • 📈 Technical Analysis (TA) – PTC Therapeutics Inc’s Price Targets

I'm going to help you getting a better view of PTC Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about PTC Therapeutics Inc

I send you an email if I find something interesting about PTC Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of PTC Therapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of PTC Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-2.15
Expected worth in 1 year
$6.98
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$9.13
Return On Investment
18.4%

For what price can you sell your share?

Current Price per Share
$49.52
Expected price per share
$34.57 - $52.98
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of PTC Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
$49.52
Intrinsic Value Per Share
$10.81 - $179.52
Total Value Per Share
$8.66 - $177.37

2.2. Growth of PTC Therapeutics Inc (5 min.)




Is PTC Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$185.7m-$740.6m-$88.9m-10.7%

How much money is PTC Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money$148.7m-$144.8m$293.5m197.4%
Net Profit Margin-16.1%-63.7%--

How much money comes from the company's main activities?

2.3. Financial Health of PTC Therapeutics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#862 / 872

Most Revenue
#35 / 872

Most Profit
#18 / 872

Most Efficient
#425 / 872
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of PTC Therapeutics Inc?

Welcome investor! PTC Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of PTC Therapeutics Inc.

First you should know what it really means to hold a share of PTC Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of PTC Therapeutics Inc is $49.52. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of PTC Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in PTC Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-2.15. Based on the TTM, the Book Value Change Per Share is $2.28 per quarter. Based on the YOY, the Book Value Change Per Share is $-1.38 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of PTC Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps10.0320.3%1.653.3%-1.83-3.7%-0.66-1.3%-1.01-2.0%-0.77-1.6%
Usd Book Value Change Per Share11.7023.6%2.284.6%-1.38-2.8%-0.08-0.2%-0.44-0.9%-0.14-0.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share11.7023.6%2.284.6%-1.38-2.8%-0.08-0.2%-0.44-0.9%-0.14-0.3%
Usd Price Per Share50.96-40.95-29.93-38.37-41.14-34.61-
Price to Earnings Ratio1.27--6.33--4.30--5.68--6.72--4.48-
Price-to-Total Gains Ratio4.35--36.30--22.82--35.01--35.24--33.35-
Price to Book Ratio-23.70--8.05--3.37--8.15-107.36-57.69-
Price-to-Total Gains Ratio4.35--36.30--22.82--35.01--35.24--33.35-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share49.52
Number of shares20
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share2.28-0.44
Usd Total Gains Per Share2.28-0.44
Gains per Quarter (20 shares)45.64-8.82
Gains per Year (20 shares)182.57-35.29
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101831730-35-45
203653560-71-80
305485390-106-115
407307220-141-150
509139050-176-185
60109510880-212-220
70127812710-247-255
80146114540-282-290
90164316370-318-325
100182618200-353-360

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%2.038.00.05.0%3.051.02.05.4%
Book Value Change Per Share1.03.00.025.0%1.011.00.08.3%2.018.00.010.0%10.030.00.025.0%17.036.03.030.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.056.00.0%
Total Gains per Share1.03.00.025.0%1.011.00.08.3%2.018.00.010.0%10.030.00.025.0%17.036.03.030.4%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of PTC Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--11.7042.282+413%-1.376+112%-0.084+101%-0.441+104%-0.140+101%
Book Value Per Share---2.150-10.419+385%-9.345+335%-7.864+266%-3.412+59%0.172-1352%
Current Ratio--3.8912.642+47%1.598+144%1.876+107%2.415+61%3.728+4%
Debt To Asset Ratio--1.0701.449-26%1.474-27%1.369-22%1.167-8%0.844+27%
Debt To Equity Ratio----0%-0%-0%69.450-100%35.350-100%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--3588260585.1201795040581.280+100%657594402.500+446%1450919043.760+147%1966893372.756+82%2055753405.378+75%
Eps--10.0311.651+508%-1.827+118%-0.659+107%-1.011+110%-0.773+108%
Ev To Ebitda Ratio--0.925-4.634+601%1.301-29%-3.151+441%-9.098+1084%14.647-94%
Ev To Sales Ratio--0.7631.295-41%0.745+2%1.497-49%3.310-77%12.583-94%
Free Cash Flow Per Share--10.0432.122+373%-0.629+106%0.073+13593%-0.382+104%-0.347+103%
Free Cash Flow To Equity Per Share--10.1522.954+244%1.399+626%1.206+741%0.722+1306%0.508+1900%
Gross Profit Margin--1.0001.0000%1.007-1%1.0020%1.013-1%0.115+768%
Intrinsic Value_10Y_max--179.521----------
Intrinsic Value_10Y_min--10.809----------
Intrinsic Value_1Y_max--2.859----------
Intrinsic Value_1Y_min---0.975----------
Intrinsic Value_3Y_max--20.121----------
Intrinsic Value_3Y_min---1.164----------
Intrinsic Value_5Y_max--51.285----------
Intrinsic Value_5Y_min--0.583----------
Market Cap3924806640.000-12%4402226585.1203336000331.280+32%2372360152.500+86%3070968960.427+43%3279074872.756+34%2752464230.378+60%
Net Profit Margin--0.737-0.161+122%-0.637+187%-0.522+171%-0.734+200%-1.144+255%
Operating Margin--0.8190.008+10474%-0.563+169%-0.413+150%-0.615+175%-1.034+226%
Operating Ratio--0.1751.098-84%1.343-87%1.373-87%1.569-89%2.399-93%
Pb Ratio-23.029+3%-23.698-8.055-66%-3.365-86%-8.145-66%107.359-122%57.691-141%
Pe Ratio1.234-3%1.270-6.327+598%-4.298+438%-5.679+547%-6.724+629%-4.478+453%
Price Per Share49.520-3%50.96040.945+24%29.933+70%38.365+33%41.144+24%34.614+47%
Price To Free Cash Flow Ratio1.233-3%1.269-16.251+1381%12.850-90%-4.750+474%292.185-100%103.205-99%
Price To Total Gains Ratio4.231-3%4.354-36.305+934%-22.816+624%-35.008+904%-35.244+909%-33.351+866%
Quick Ratio--4.6773.284+42%1.803+159%2.217+111%3.435+36%5.600-16%
Return On Assets--0.3260.045+633%-0.097+130%-0.046+114%-0.053+116%-0.065+120%
Return On Equity----0%-0%-0%-5.1280%-2.6420%
Total Gains Per Share--11.7042.282+413%-1.376+112%-0.084+101%-0.441+104%-0.140+101%
Usd Book Value---185760000.000-829591000.000+347%-740637250.000+299%-624556833.333+236%-271215800.000+46%13225425.000-1505%
Usd Book Value Change Per Share--11.7042.282+413%-1.376+112%-0.084+101%-0.441+104%-0.140+101%
Usd Book Value Per Share---2.150-10.419+385%-9.345+335%-7.864+266%-3.412+59%0.172-1352%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--3588260585.1201795040581.280+100%657594402.500+446%1450919043.760+147%1966893372.756+82%2055753405.378+75%
Usd Eps--10.0311.651+508%-1.827+118%-0.659+107%-1.011+110%-0.773+108%
Usd Free Cash Flow--867571000.000186060250.000+366%-49867250.000+106%11779166.667+7265%-26710600.000+103%-25718175.000+103%
Usd Free Cash Flow Per Share--10.0432.122+373%-0.629+106%0.073+13593%-0.382+104%-0.347+103%
Usd Free Cash Flow To Equity Per Share--10.1522.954+244%1.399+626%1.206+741%0.722+1306%0.508+1900%
Usd Market Cap3924806640.000-12%4402226585.1203336000331.280+32%2372360152.500+86%3070968960.427+43%3279074872.756+34%2752464230.378+60%
Usd Price Per Share49.520-3%50.96040.945+24%29.933+70%38.365+33%41.144+24%34.614+47%
Usd Profit--866562000.000148710750.000+483%-144805250.000+117%-46302333.333+105%-76586400.000+109%-59442875.000+107%
Usd Revenue--1176096000.000443189500.000+165%231889500.000+407%289230250.000+307%223529700.000+426%135413500.000+769%
Usd Total Gains Per Share--11.7042.282+413%-1.376+112%-0.084+101%-0.441+104%-0.140+101%
 EOD+3 -5MRQTTM+31 -4YOY+32 -43Y+31 -55Y+33 -410Y+28 -9

3.3 Fundamental Score

Let's check the fundamental score of PTC Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-151.234
Price to Book Ratio (EOD)Between0-1-23.029
Net Profit Margin (MRQ)Greater than00.737
Operating Margin (MRQ)Greater than00.819
Quick Ratio (MRQ)Greater than14.677
Current Ratio (MRQ)Greater than13.891
Debt to Asset Ratio (MRQ)Less than11.070
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.050.326
Total7/10 (70.0%)

3.4 Technical Score

Let's check the technical score of PTC Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.116
Ma 20Greater thanMa 5049.673
Ma 50Greater thanMa 10048.188
Ma 100Greater thanMa 20049.340
OpenGreater thanClose48.830
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Fundamental data was last updated by Penke on 2025-06-20 13:43:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit PTC Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare PTC Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 73.7% means that $0.74 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of PTC Therapeutics Inc:

  • The MRQ is 73.7%. The company is making a huge profit. +2
  • The TTM is -16.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ73.7%TTM-16.1%+89.8%
TTM-16.1%YOY-63.7%+47.6%
TTM-16.1%5Y-73.4%+57.3%
5Y-73.4%10Y-114.4%+41.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ73.7%-93.6%+167.3%
TTM-16.1%-140.9%+124.8%
YOY-63.7%-197.6%+133.9%
3Y-52.2%-248.5%+196.3%
5Y-73.4%-343.4%+270.0%
10Y-114.4%-496.2%+381.8%
4.3.1.2. Return on Assets

Shows how efficient PTC Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare PTC Therapeutics Inc to the Biotechnology industry mean.
  • 32.6% Return on Assets means that PTC Therapeutics Inc generated $0.33 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of PTC Therapeutics Inc:

  • The MRQ is 32.6%. Using its assets, the company is very efficient in making profit. +2
  • The TTM is 4.5%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ32.6%TTM4.5%+28.2%
TTM4.5%YOY-9.7%+14.1%
TTM4.5%5Y-5.3%+9.8%
5Y-5.3%10Y-6.5%+1.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ32.6%-11.6%+44.2%
TTM4.5%-11.6%+16.1%
YOY-9.7%-11.4%+1.7%
3Y-4.6%-11.8%+7.2%
5Y-5.3%-12.0%+6.7%
10Y-6.5%-13.7%+7.2%
4.3.1.3. Return on Equity

Shows how efficient PTC Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare PTC Therapeutics Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means PTC Therapeutics Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of PTC Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-512.8%+512.8%
5Y-512.8%10Y-264.2%-248.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--13.5%+13.5%
TTM--14.9%+14.9%
YOY--14.6%+14.6%
3Y--16.8%+16.8%
5Y-512.8%-17.5%-495.3%
10Y-264.2%-19.9%-244.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of PTC Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient PTC Therapeutics Inc is operating .

  • Measures how much profit PTC Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare PTC Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 81.9% means the company generated $0.82  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of PTC Therapeutics Inc:

  • The MRQ is 81.9%. The company is operating very efficient. +2
  • The TTM is 0.8%. The company is operating inefficient. -1
Trends
Current periodCompared to+/- 
MRQ81.9%TTM0.8%+81.1%
TTM0.8%YOY-56.3%+57.1%
TTM0.8%5Y-61.5%+62.3%
5Y-61.5%10Y-103.4%+41.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ81.9%-232.5%+314.4%
TTM0.8%-250.5%+251.3%
YOY-56.3%-209.2%+152.9%
3Y-41.3%-234.1%+192.8%
5Y-61.5%-346.1%+284.6%
10Y-103.4%-477.5%+374.1%
4.3.2.2. Operating Ratio

Measures how efficient PTC Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.18 means that the operating costs are $0.18 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of PTC Therapeutics Inc:

  • The MRQ is 0.175. The company is very efficient in keeping operating costs low. +2
  • The TTM is 1.098. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.175TTM1.098-0.923
TTM1.098YOY1.343-0.245
TTM1.0985Y1.569-0.471
5Y1.56910Y2.399-0.830
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1752.111-1.936
TTM1.0982.694-1.596
YOY1.3433.096-1.753
3Y1.3733.652-2.279
5Y1.5694.745-3.176
10Y2.3996.614-4.215
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of PTC Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if PTC Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.89 means the company has $3.89 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of PTC Therapeutics Inc:

  • The MRQ is 3.891. The company is very able to pay all its short-term debts. +2
  • The TTM is 2.642. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ3.891TTM2.642+1.249
TTM2.642YOY1.598+1.044
TTM2.6425Y2.415+0.226
5Y2.41510Y3.728-1.313
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.8913.661+0.230
TTM2.6423.846-1.204
YOY1.5984.140-2.542
3Y1.8764.688-2.812
5Y2.4155.746-3.331
10Y3.7286.147-2.419
4.4.3.2. Quick Ratio

Measures if PTC Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare PTC Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 4.68 means the company can pay off $4.68 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of PTC Therapeutics Inc:

  • The MRQ is 4.677. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.284. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.677TTM3.284+1.393
TTM3.284YOY1.803+1.480
TTM3.2845Y3.435-0.151
5Y3.43510Y5.600-2.165
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.6772.848+1.829
TTM3.2843.169+0.115
YOY1.8033.786-1.983
3Y2.2174.311-2.094
5Y3.4355.703-2.268
10Y5.6006.368-0.768
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of PTC Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of PTC Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare PTC Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.07 means that PTC Therapeutics Inc assets are financed with 107.0% credit (debt) and the remaining percentage (100% - 107.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of PTC Therapeutics Inc:

  • The MRQ is 1.070. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 1.449. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.070TTM1.449-0.379
TTM1.449YOY1.474-0.024
TTM1.4495Y1.167+0.282
5Y1.16710Y0.844+0.324
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0700.329+0.741
TTM1.4490.349+1.100
YOY1.4740.331+1.143
3Y1.3690.340+1.029
5Y1.1670.349+0.818
10Y0.8440.379+0.465
4.5.4.2. Debt to Equity Ratio

Measures if PTC Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare PTC Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of PTC Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y69.450-69.450
5Y69.45010Y35.350+34.100
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.379-0.379
TTM-0.437-0.437
YOY-0.414-0.414
3Y-0.450-0.450
5Y69.4500.464+68.986
10Y35.3500.515+34.835
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings PTC Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare PTC Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of 1.27 means the investor is paying $1.27 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of PTC Therapeutics Inc:

  • The EOD is 1.234. Based on the earnings, the company is cheap. +2
  • The MRQ is 1.270. Based on the earnings, the company is cheap. +2
  • The TTM is -6.327. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD1.234MRQ1.270-0.036
MRQ1.270TTM-6.327+7.597
TTM-6.327YOY-4.298-2.029
TTM-6.3275Y-6.724+0.397
5Y-6.72410Y-4.478-2.245
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.234-2.356+3.590
MRQ1.270-2.077+3.347
TTM-6.327-2.574-3.753
YOY-4.298-3.760-0.538
3Y-5.679-3.773-1.906
5Y-6.724-6.193-0.531
10Y-4.478-6.876+2.398
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of PTC Therapeutics Inc:

  • The EOD is 1.233. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 1.269. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is -16.251. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD1.233MRQ1.269-0.036
MRQ1.269TTM-16.251+17.519
TTM-16.251YOY12.850-29.101
TTM-16.2515Y292.185-308.436
5Y292.18510Y103.205+188.980
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.233-3.246+4.479
MRQ1.269-2.705+3.974
TTM-16.251-3.704-12.547
YOY12.850-4.402+17.252
3Y-4.750-5.070+0.320
5Y292.185-8.477+300.662
10Y103.205-9.305+112.510
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of PTC Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -23.70 means the investor is paying $-23.70 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of PTC Therapeutics Inc:

  • The EOD is -23.029. Based on the equity, the company is expensive. -2
  • The MRQ is -23.698. Based on the equity, the company is expensive. -2
  • The TTM is -8.055. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-23.029MRQ-23.698+0.670
MRQ-23.698TTM-8.055-15.644
TTM-8.055YOY-3.365-4.690
TTM-8.0555Y107.359-115.413
5Y107.35910Y57.691+49.668
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-23.0292.038-25.067
MRQ-23.6981.843-25.541
TTM-8.0552.125-10.180
YOY-3.3652.442-5.807
3Y-8.1452.492-10.637
5Y107.3593.652+103.707
10Y57.6914.311+53.380
4.6.2. Total Gains per Share

2.4. Latest News of PTC Therapeutics Inc

Does PTC Therapeutics Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from PTC Therapeutics Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-29
08:22
Biotech Stocks Facing FDA Decision In July 2025Read
2025-06-20
22:06
Truist Initiates PTC Therapeutics (PTCT) Coverage with Buy Rating on Drug LaunchesRead
2025-06-19
22:40
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Read
2025-06-19
22:30
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Read
2025-06-14
14:26
PTC Therapeutics' SWOT analysis: biotech stock's potential in rare disease marketRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of PTC Therapeutics Inc.

4.8.1. Institutions holding PTC Therapeutics Inc

Institutions are holding 101.063% of the shares of PTC Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Vanguard Group Inc10.86010.00798607372-571450-6.2257
2025-03-31BlackRock Inc9.80130.00837768217-130584-1.6532
2025-03-31RTW INVESTMENTS, LLC9.44165.83237483127900001.2173
2025-03-31Armistice Capital, LLC6.85724.15085434843-943157-14.7877
2025-03-31Wellington Management Company LLP6.83750.0531541917263204913.2031
2025-03-31HHG PLC3.68010.0867291672959081425.4014
2025-03-31The Toronto-Dominion Bank3.29710.26092613196-673533-20.4925
2025-03-31State Street Corp3.09740.00522454896-253100-9.3464
2025-03-31FMR Inc2.54050.006620135621193518145.5432
2025-03-31Geode Capital Management, LLC2.36430.00751873886768704.2776
2024-12-31D. E. Shaw & Co LP1.94590.051115422921227538.6474
2025-03-31Driehaus Capital Management LLC1.90850.7431151264547158645.2987
2025-03-31Camber Capital Management LLC1.89262.71551500000-1700000-53.125
2025-03-31Point72 Asset Management, L.P.1.73310.15981373573-69789-4.8352
2025-03-31Franklin Resources Inc1.60620.01871273008-5180-0.4053
2025-03-31Citadel Advisors Llc1.47320.01131167621709606154.9307
2024-12-31Nuveen Asset Management, LLC1.35990.0137107779427363834.028
2024-12-31UBS Group AG1.35140.00891071051905980548.8426
2025-03-31Pictet Asset Manangement SA1.31530.06104245830607041.5637
2025-03-31Nuveen, LLC1.27330.0156100916810091680
Total 74.636514.21759154610+2035259+3.4%

4.9.2. Funds holding PTC Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Vanguard Health Care Inv4.16430.4318330051450390318.0183
2025-04-30Vanguard Total Stock Mkt Idx Inv3.11270.00722467008451301.8634
2025-04-30Vanguard Small Cap Index2.44280.06881936098109450.5685
2025-05-31iShares Russell 2000 ETF2.41110.1506191097600
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr1.50150.0582119005264310.5433
2025-04-30Vanguard Small Cap Growth Index Inv1.36090.1611078601-813-0.0753
2025-03-31Fidelity Small Cap Index0.95880.160275992754920.728
2025-05-31Franklin Biotechnology Discv A(acc)USD0.94412.902774823100
2025-05-31SPDR® S&P Biotech ETF0.82860.679265675138780.594
2025-03-31Vanguard Strategic Equity Inv0.7520.3554596046-138628-18.8693
2025-04-30Fidelity Select Biotechnology0.63420.642150261117920055.4094
2025-05-31iShares Russell 2000 Growth ETF0.63320.220450184200
2025-03-31Janus Henderson Global Life Sciences D0.61630.5297488447-1806-0.3684
2025-03-31Janus Henderson Global Life Sciences0.61630.5292488447264865.7334
2025-05-31iShares Biotechnology ETF0.5740.442245497400
2025-04-30Janus Henderson Glb Life Scn I2 USD0.56950.6014514005403613.5986
2025-04-30Franklin Biotechnology Discovery A0.55623.101244081100
2025-05-31State St Russell Sm/Mid Cp® Indx SL Cl I0.55330.051743851552001.2001
2025-04-30Fidelity Extended Market Index0.53750.059426035-840-0.1968
2025-03-31Fidelity Small Cap Growth0.53270.31964222004222000
Total 24.311.471219259486+1120814+5.8%

5.3. Insider Transactions

Insiders are holding 2.42% of the shares of PTC Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-05-16Mark Elliott BouldingSELL88346.02
2025-05-15Mark Elliott BouldingSELL192946.18
2025-04-22Matthew B KleinSELL280448.74
2025-04-02Lee Scott GoldenSELL89746.95
2025-03-13Stephanie OkeySELL500054
2025-03-12Mark Elliott BouldingSELL1552153.3
2025-03-04Allan Steven JacobsonSELL123051.52
2025-02-19Pierre GravierSELL116850.1
2025-02-19Neil Gregory AlmsteadSELL130050.1
2025-02-19Mark Elliott BouldingSELL133350.1
2025-02-19Lee Scott GoldenSELL79550.1
2025-02-19Eric PauwelsSELL137850.1
2025-02-19Christine Marie UtterSELL87950.1
2025-01-07Christine Marie UtterSELL129145.34
2025-01-07Eric PauwelsSELL159945.34
2025-01-07Lee Scott GoldenSELL81045.34
2025-01-07Mark Elliott BouldingSELL154345.34
2025-01-07Neil Gregory AlmsteadSELL126545.34
2024-12-31Matthew B KleinSELL827945.16
2024-12-02Christine Marie UtterSELL1780051.77
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-03-312024-06-302024-09-302024-12-312025-03-31
Income before Tax  -84,696-1,037-85,733-12,258-97,9913,292-94,6991,024,527929,828
Net Income  -91,576-7,603-99,179-7,475-106,65440,768-65,886932,448866,562
EBIT  -43,8621,619-42,243-18,753-60,9967,357-53,6391,016,643963,004
Operating Income  -45,55312,196-33,357-21,153-54,510-107,879-162,3891,132,614970,225
Net Income from Continuing Operations  -91,576-7,603-99,179-7,475-106,65440,768-65,886932,448866,562



5.2. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets2,655,387
Total Liabilities2,841,147
Total Stockholder Equity-185,760
 As reported
Total Liabilities 2,841,147
Total Stockholder Equity+ -185,760
Total Assets = 2,655,387

Assets

Total Assets2,655,387
Total Current Assets2,316,406
Long-term Assets338,981
Total Current Assets
Cash And Cash Equivalents 1,480,231
Short-term Investments 546,950
Net Receivables 210,495
Inventory 21,675
Other Current Assets 57,055
Total Current Assets  (as reported)2,316,406
Total Current Assets  (calculated)2,316,406
+/-0
Long-term Assets
Property Plant Equipment 116,776
Goodwill 82,341
Intangible Assets 118,448
Long-term Assets Other 21,416
Long-term Assets  (as reported)338,981
Long-term Assets  (calculated)338,981
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities595,391
Long-term Liabilities2,245,756
Total Stockholder Equity-185,760
Total Current Liabilities
Short-term Debt 16,511
Accounts payable 15,150
Other Current Liabilities 486,275
Total Current Liabilities  (as reported)595,391
Total Current Liabilities  (calculated)517,936
+/- 77,455
Long-term Liabilities
Long term Debt 285,712
Capital Lease Obligations Min Short Term Debt87,392
Long-term Liabilities Other 1,872,652
Long-term Liabilities  (as reported)2,245,756
Long-term Liabilities  (calculated)2,245,756
+/-0
Total Stockholder Equity
Common Stock78
Retained Earnings -2,780,311
Accumulated Other Comprehensive Income -13,949
Other Stockholders Equity 2,608,422
Total Stockholder Equity (as reported)-185,760
Total Stockholder Equity (calculated)-185,760
+/-0
Other
Capital Stock78
Cash and Short Term Investments 2,027,181
Common Stock Shares Outstanding 86,386
Current Deferred Revenue12,833
Liabilities and Stockholders Equity 2,655,387
Net Debt -1,090,616
Net Invested Capital 99,952
Net Working Capital 1,721,015
Property Plant and Equipment Gross 116,776
Short Long Term Debt Total 389,615



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312005-12-312004-12-31
> Total Assets 
38,968
43,974
44,148
0
0
0
13,072
64,406
175,468
167,244
151,903
255,840
237,558
220,795
333,219
299,520
273,822
396,100
368,041
335,232
305,563
288,177
269,345
248,645
383,078
367,720
391,653
379,411
511,773
1,028,627
1,119,222
1,283,911
1,291,572
1,641,486
1,623,782
1,545,592
1,476,637
2,181,059
2,208,278
2,111,941
2,058,669
2,007,325
1,938,056
1,799,591
1,804,057
1,576,398
1,705,619
1,608,839
1,338,124
1,259,885
1,903,181
1,789,629
1,916,355
1,842,236
1,705,024
2,655,387
2,655,3871,705,0241,842,2361,916,3551,789,6291,903,1811,259,8851,338,1241,608,8391,705,6191,576,3981,804,0571,799,5911,938,0562,007,3252,058,6692,111,9412,208,2782,181,0591,476,6371,545,5921,623,7821,641,4861,291,5721,283,9111,119,2221,028,627511,773379,411391,653367,720383,078248,645269,345288,177305,563335,232368,041396,100273,822299,520333,219220,795237,558255,840151,903167,244175,46864,40613,07200044,14843,97438,968
   > Total Current Assets 
0
0
0
0
0
0
4,595
56,572
168,158
160,138
145,024
249,380
230,314
213,516
323,571
289,761
264,574
384,164
355,949
326,434
297,434
280,607
261,286
240,727
226,972
221,259
249,063
241,996
375,646
313,281
320,857
479,079
474,966
806,862
779,284
691,922
605,024
1,244,174
1,231,745
1,122,365
1,066,233
1,011,140
773,376
774,009
694,676
517,262
693,785
613,392
589,691
540,362
1,218,629
1,168,738
1,357,910
1,281,550
1,365,531
2,316,406
2,316,4061,365,5311,281,5501,357,9101,168,7381,218,629540,362589,691613,392693,785517,262694,676774,009773,3761,011,1401,066,2331,122,3651,231,7451,244,174605,024691,922779,284806,862474,966479,079320,857313,281375,646241,996249,063221,259226,972240,727261,286280,607297,434326,434355,949384,164264,574289,761323,571213,516230,314249,380145,024160,138168,15856,5724,595000000
       Cash And Cash Equivalents 
6,777
10,964
28,432
0
0
0
2,726
54,747
165,678
24,045
15,414
115,855
21,172
52,873
315,241
280,467
255,219
140,712
338,925
40,165
35,658
50,286
231,666
54,106
181,069
141,838
191,246
97,675
223,788
206,913
227,586
407,162
136,094
523,577
686,563
123,287
158,461
433,970
208,812
146,632
177,347
189,818
773,376
144,178
158,158
104,424
279,834
167,495
208,393
165,157
594,001
548,355
654,779
526,001
779,709
1,480,231
1,480,231779,709526,001654,779548,355594,001165,157208,393167,495279,834104,424158,158144,178773,376189,818177,347146,632208,812433,970158,461123,287686,563523,577136,094407,162227,586206,913223,78897,675191,246141,838181,06954,106231,66650,28635,65840,165338,925140,712255,219280,467315,24152,87321,172115,85515,41424,045165,67854,7472,72600028,43210,9646,777
       Short-term Investments 
26,210
26,876
0
0
0
0
0
0
11,583
133,183
127,053
130,730
205,687
156,516
265,493
243,642
225,999
230,809
280,903
258,547
237,235
198,052
173,345
148,471
48,058
27,472
79,454
80,595
72,318
42,491
58,088
206,018
227,447
185,072
398,535
472,572
340,430
707,049
894,838
841,774
769,734
678,125
583,658
443,615
347,387
184,008
130,871
118,808
129,550
129,653
282,738
336,458
438,514
487,356
359,987
546,950
546,950359,987487,356438,514336,458282,738129,653129,550118,808130,871184,008347,387443,615583,658678,125769,734841,774894,838707,049340,430472,572398,535185,072227,447206,01858,08842,49172,31880,59579,45427,47248,058148,471173,345198,052237,235258,547280,903230,809225,999243,642265,493156,516205,687130,730127,053133,18311,58300000026,87626,210
       Net Receivables 
0
0
0
0
0
0
1,014
946
871
784
958
838
858
1,296
4,445
3,178
5,114
8,016
11,094
22,618
19,765
27,409
24,929
32,173
33,767
38,744
40,394
45,611
59,383
42,197
67,907
46,350
77,104
60,383
55,538
52,623
53,644
56,786
69,929
94,124
78,801
96,645
110,455
141,288
135,943
124,456
155,614
201,867
177,503
165,718
161,022
198,460
187,150
199,976
158,554
210,495
210,495158,554199,976187,150198,460161,022165,718177,503201,867155,614124,456135,943141,288110,45596,64578,80194,12469,92956,78653,64452,62355,53860,38377,10446,35067,90742,19759,38345,61140,39438,74433,76732,17324,92927,40919,76522,61811,0948,0165,1143,1784,4451,2968588389587848719461,014000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,300
1,700
1,354
6,912
7,792
10,754
12,355
13,852
13,660
16,117
16,219
16,897
17,107
19,285
19,133
18,373
19,481
18,697
16,234
16,441
15,613
15,856
15,281
15,004
14,812
21,808
26,649
32,018
35,752
30,577
30,058
31,826
35,671
23,194
21,675
21,67523,19435,67131,82630,05830,57735,75232,01826,64921,80814,81215,00415,28115,85615,61316,44116,23418,69719,48118,37319,13319,28517,10716,89716,21916,11713,66013,85212,35510,7547,7926,9121,3541,7001,300000000000000000000000
   > Long-term Assets 
0
0
0
0
0
0
8,477
7,833
7,310
7,106
6,878
6,460
7,244
7,279
9,648
9,759
9,248
11,936
12,092
8,798
8,129
7,570
8,059
7,918
156,106
146,461
142,590
137,415
136,127
715,346
798,365
804,832
816,606
834,624
844,498
853,670
871,613
936,885
976,533
989,576
992,436
996,185
1,164,680
1,025,582
1,109,381
1,059,136
1,011,834
995,447
748,433
719,523
684,552
620,891
558,445
560,686
339,493
338,981
338,981339,493560,686558,445620,891684,552719,523748,433995,4471,011,8341,059,1361,109,3811,025,5821,164,680996,185992,436989,576976,533936,885871,613853,670844,498834,624816,606804,832798,365715,346136,127137,415142,590146,461156,1067,9188,0597,5708,1298,79812,09211,9369,2489,7599,6487,2797,2446,4606,8787,1067,3107,8338,477000000
       Property Plant Equipment 
5,205
4,702
10,795
0
0
0
8,280
7,676
7,154
6,943
6,729
6,328
6,417
6,193
9,159
9,408
9,017
8,799
8,974
8,426
7,601
7,059
7,429
7,059
6,839
6,882
8,376
8,302
8,217
8,805
12,694
14,540
15,391
18,484
21,549
26,169
26,806
113,951
118,241
119,505
123,604
125,053
130,006
135,181
206,548
171,790
175,020
179,023
178,815
179,103
178,985
183,965
123,122
122,640
117,655
116,776
116,776117,655122,640123,122183,965178,985179,103178,815179,023175,020171,790206,548135,181130,006125,053123,604119,505118,241113,95126,80626,16921,54918,48415,39114,54012,6948,8058,2178,3028,3766,8826,8397,0597,4297,0597,6018,4268,9748,7999,0179,4089,1596,1936,4176,3286,7296,9437,1547,6768,28000010,7954,7025,205
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
148,138
138,422
132,993
127,565
126,290
100,309
82,341
82,341
82,341
82,341
82,341
82,341
82,341
82,341
82,341
82,341
82,341
82,341
82,341
82,341
82,341
82,341
82,341
82,341
82,341
82,341
82,341
82,341
82,341
82,341
82,341
82,341
82,34182,34182,34182,34182,34182,34182,34182,34182,34182,34182,34182,34182,34182,34182,34182,34182,34182,34182,34182,34182,34182,34182,34182,34182,34182,341100,309126,290127,565132,993138,422148,138000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
148,138
138,422
132,993
127,565
126,290
604,612
701,031
694,955
702,729
702,910
710,500
705,294
708,814
712,536
715,328
712,574
717,079
723,260
724,841
763,665
760,154
749,890
705,891
686,205
451,629
423,342
379,497
330,040
329,879
330,368
118,794
118,448
118,448118,794330,368329,879330,040379,497423,342451,629686,205705,891749,890760,154763,665724,841723,260717,079712,574715,328712,536708,814705,294710,500702,910702,729694,955701,031604,612126,290127,565132,993138,422148,138000000000000000000000000
       Long-term Assets Other 
0
0
0
0
0
0
197
158
156
163
149
132
827
1,086
489
351
231
3,137
3,118
372
528
511
630
859
1,129
1,157
1,221
1,548
1,620
1,620
2,299
12,996
16,145
30,889
30,108
39,866
53,652
28,057
31,323
67,656
61,912
58,031
227,492
36,895
60,338
55,115
48,582
47,878
35,648
34,737
19,963
8,277
9,340
25,337
20,703
21,416
21,41620,70325,3379,3408,27719,96334,73735,64847,87848,58255,11560,33836,895227,49258,03161,91267,65631,32328,05753,65239,86630,10830,88916,14512,9962,2991,6201,6201,5481,2211,1571,1298596305115283723,1183,1372313514891,086827132149163156158197000000
> Total Liabilities 
4,355
5,573
68,373
0
0
0
32,267
30,328
175,468
16,212
15,360
11,498
13,802
19,499
34,752
26,200
25,241
126,949
69,574
139,231
139,939
148,000
149,762
147,818
213,347
221,838
235,216
229,103
244,371
642,537
768,495
770,969
802,887
977,832
1,029,452
1,016,858
904,143
1,670,105
1,726,296
1,819,365
1,862,092
1,902,399
1,936,618
1,890,172
1,986,275
1,803,302
2,052,705
2,066,400
1,917,392
1,930,695
2,721,736
2,683,545
2,896,536
2,896,588
2,803,095
2,841,147
2,841,1472,803,0952,896,5882,896,5362,683,5452,721,7361,930,6951,917,3922,066,4002,052,7051,803,3021,986,2751,890,1721,936,6181,902,3991,862,0921,819,3651,726,2961,670,105904,1431,016,8581,029,452977,832802,887770,969768,495642,537244,371229,103235,216221,838213,347147,818149,762148,000139,939139,23169,574126,94925,24126,20034,75219,49913,80211,49815,36016,212175,46830,32832,26700068,3735,5734,355
   > Total Current Liabilities 
4,128
4,646
43,145
0
0
0
28,159
27,327
19,788
13,921
13,133
9,239
11,583
17,262
32,475
23,905
23,082
31,695
45,386
43,889
42,909
48,926
49,624
45,418
67,985
71,899
82,048
72,716
86,474
114,922
166,796
143,046
173,959
183,500
235,857
217,668
201,843
253,822
277,333
250,949
290,962
465,261
509,348
476,776
567,371
420,076
406,236
441,634
476,342
492,118
603,100
574,546
609,803
610,712
580,981
595,391
595,391580,981610,712609,803574,546603,100492,118476,342441,634406,236420,076567,371476,776509,348465,261290,962250,949277,333253,822201,843217,668235,857183,500173,959143,046166,796114,92286,47472,71682,04871,89967,98545,41849,62448,92642,90943,88945,38631,69523,08223,90532,47517,26211,5839,23913,13313,92119,78827,32728,15900043,1454,6464,128
       Short-term Debt 
0
0
0
0
0
0
4,444
3,823
2,747
84
48
12
0
0
0
0
0
0
91,848
0
0
28,521
40,874
39,380
57,934
58,060
61,164
59,033
1,666
6,667
11,667
16,667
20,000
20,000
25,153
20,000
22,513
29,269
8,741
42,176
53,791
211,710
159,813
168,003
172,052
22,956
84,519
11,455
24,858
28,628
210,316
16,520
32,012
16,755
271,184
16,511
16,511271,18416,75532,01216,520210,31628,62824,85811,45584,51922,956172,052168,003159,813211,71053,79142,1768,74129,26922,51320,00025,15320,00020,00016,66711,6676,6671,66659,03361,16458,06057,93439,38040,87428,5210091,8480000001248842,7473,8234,444000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
91,848
0
0
0
98,216
99,895
141,242
143,091
144,971
146,878
1,666
6,667
11,667
16,667
20,000
20,000
20,000
20,000
18,333
0
0
0
0
149,358
149,540
149,721
149,908
0
72,149
0
0
0
194,314
0
0
0
257,821
0
0257,821000194,31400072,1490149,908149,721149,540149,358000018,33320,00020,00020,00020,00016,66711,6676,6671,666146,878144,971143,091141,24299,89598,21600091,848000000000000000000
       Accounts payable 
1,703
1,183
1,878
0
0
0
622
269
425
1,017
1,124
387
613
518
4,128
3,139
3,406
8,715
11,940
16,023
16,800
19,238
6,298
3,579
6,062
5,994
15,282
3,104
4,364
6,538
6,001
9,786
10,219
8,959
10,324
16,074
15,465
15,663
18,665
19,114
20,820
21,462
23,033
18,365
22,881
20,862
27,268
26,311
25,741
19,152
6,045
27,459
24,279
13,292
17,274
15,150
15,15017,27413,29224,27927,4596,04519,15225,74126,31127,26820,86222,88118,36523,03321,46220,82019,11418,66515,66315,46516,07410,3248,95910,2199,7866,0016,5384,3643,10415,2825,9946,0623,5796,29819,23816,80016,02311,9408,7153,4063,1394,1285186133871,1241,0174252696220001,8781,1831,703
       Other Current Liabilities 
1,501
2,985
34,127
0
0
0
6,402
11,201
9,633
9,188
11,082
8,348
10,728
15,975
24,993
20,393
19,676
22,980
33,307
27,470
25,383
257
865
265
1,387
1,723
1,665
1,279
80,444
99,713
145,412
111,096
135,735
145,731
192,138
172,956
156,163
203,582
241,461
183,863
215,733
232,089
60,751
285,859
364,856
376,258
288,386
397,924
414,594
440,292
385,938
528,734
549,813
574,653
282,317
486,275
486,275282,317574,653549,813528,734385,938440,292414,594397,924288,386376,258364,856285,85960,751232,089215,733183,863241,461203,582156,163172,956192,138145,731135,735111,096145,41299,71380,4441,2791,6651,7231,38726586525725,38327,47033,30722,98019,67620,39324,99315,97510,7288,34811,0829,1889,63311,2016,40200034,1272,9851,501
   > Long-term Liabilities 
0
0
0
0
0
0
4,108
3,001
2,760
2,290
2,227
2,259
2,219
2,237
2,277
2,295
2,159
95,254
96,654
95,342
97,030
99,074
100,138
102,400
145,362
149,939
153,168
156,387
157,897
527,615
601,699
627,923
628,928
794,332
793,595
799,190
702,300
1,416,283
1,448,963
1,568,416
1,571,130
1,437,138
1,165,419
1,413,396
1,418,904
1,383,226
1,646,469
1,624,766
1,441,050
1,438,577
2,118,636
2,108,999
2,286,733
2,285,876
2,222,114
2,245,756
2,245,7562,222,1142,285,8762,286,7332,108,9992,118,6361,438,5771,441,0501,624,7661,646,4691,383,2261,418,9041,413,3961,165,4191,437,1381,571,1301,568,4161,448,9631,416,283702,300799,190793,595794,332628,928627,923601,699527,615157,897156,387153,168149,939145,362102,400100,13899,07497,03095,34296,65495,2542,1592,2952,2772,2372,2192,2592,2272,2902,7603,0014,108000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
93,198
94,608
93,366
94,936
96,559
98,216
99,895
141,242
143,091
144,971
146,878
147,204
144,258
141,347
138,468
135,683
293,149
293,859
294,574
297,029
302,971
309,145
430,038
430,496
281,604
281,894
282,176
282,460
282,749
571,722
572,091
572,643
0
0
0
0
0
0
0
0000000572,643572,091571,722282,749282,460282,176281,894281,604430,496430,038309,145302,971297,029294,574293,859293,149135,683138,468141,347144,258147,204146,878144,971143,091141,24299,89598,21696,55994,93693,36694,60893,19800000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
-4,444
-3,823
-2,747
-84
-48
-12
0
0
0
0
0
0
-91,848
0
0
-28,521
-40,874
-39,380
-57,934
-58,060
-61,164
-59,033
-1,666
-6,667
-11,667
-16,667
-20,000
-20,000
-25,153
-20,000
3,698
82,123
102,552
64,767
52,143
-107,133
-55,868
-67,755
-4,952
109,321
47,386
117,626
105,180
102,552
-79,503
120,411
78,686
98,344
-167,300
87,392
87,392-167,30098,34478,686120,411-79,503102,552105,180117,62647,386109,321-4,952-67,755-55,868-107,13352,14364,767102,55282,1233,698-20,000-25,153-20,000-20,000-16,667-11,667-6,667-1,666-59,033-61,164-58,060-57,934-39,380-40,874-28,52100-91,848000000-12-48-84-2,747-3,823-4,444000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
2,518
2,290
2,227
2,259
2,219
2,237
2,277
2,295
2,159
2,056
2,046
1,976
2,094
2,515
335
311
292
269
243
209
10,693
268,157
338,320
367,423
371,213
379,151
368,874
373,754
274,409
982,449
1,003,083
663,227
666,221
671,925
1,008,266
994,110
999,334
963,367
971,913
949,844
816,479
657,610
141
1,611,972
1,830,024
1,824,517
21,426
1,872,652
1,872,65221,4261,824,5171,830,0241,611,972141657,610816,479949,844971,913963,367999,334994,1101,008,266671,925666,221663,2271,003,083982,449274,409373,754368,874379,151371,213367,423338,320268,15710,6932092432692923113352,5152,0941,9762,0462,0562,1592,2952,2772,2372,2192,2592,2272,2902,51800000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
242
0
0
0
0
0
0
0
0
0
0
0
0
0
1,587
2,194
3,828
6,579
7,954
9,300
0
115,200
122,032
122,032
122,032
122,032
130,862
130,862
130,862
130,863
136,735
136,735
136,735
136,733
137,110
137,110
137,110
137,110
102,834
102,831
51,928
0
0
0
0
0
0
0
000000051,928102,831102,834137,110137,110137,110137,110136,733136,735136,735136,735130,863130,862130,862130,862122,032122,032122,032122,032115,20009,3007,9546,5793,8282,1941,587000000000000024200000000
> Total Stockholder Equity
34,613
38,401
0
0
0
0
-19,195
34,077
152,920
151,033
136,542
244,342
223,756
201,296
298,467
273,320
248,581
269,151
298,467
196,001
165,624
140,177
119,583
100,827
169,731
145,882
156,437
150,308
267,402
386,090
350,727
512,942
488,685
663,654
594,330
528,734
572,494
510,954
481,982
292,576
196,577
104,926
1,438
-90,581
-182,218
-226,904
-347,086
-457,561
-579,268
-670,810
-818,555
-893,916
-980,181
-1,054,352
-1,098,071
-185,760
-185,760-1,098,071-1,054,352-980,181-893,916-818,555-670,810-579,268-457,561-347,086-226,904-182,218-90,5811,438104,926196,577292,576481,982510,954572,494528,734594,330663,654488,685512,942350,727386,090267,402150,308156,437145,882169,731100,827119,583140,177165,624196,001298,467269,151248,581273,320298,467201,296223,756244,342136,542151,033152,92034,077-19,195000038,40134,613
   Common Stock
0
0
0
0
0
0
1
14
24
24
24
30
30
30
33
33
34
34
34
34
34
34
34
34
41
41
42
42
47
51
51
58
58
61
62
62
67
68
70
70
70
70
71
71
71
71
72
73
75
75
75
76
76
76
77
78
787776767675757573727171717170707070686762626158585151474242414134343434343434343333303030242424141000000
   Retained Earnings Total Equity0000000-2,994,816-2,795,933-2,656,974-2,486,085-2,376,770-2,224,683-2,097,957-1,954,717-1,821,093-1,702,723-1,628,877-1,554,523-1,484,831-1,303,404-1,190,499-1,112,822-1,052,825-1,011,036-938,923-890,600-839,624-830,100-814,100-815,378-781,640-764,165-735,108-708,313-673,145-634,231-592,998-542,050-498,827-460,466-422,551-395,282-368,000-342,896-328,798-310,912-306,49600000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
-20,286
0
-1
-40
70
80
90
-69
-737
-736
-495
-1,127
-1,200
1,084
885
756
-1,485
-876
1,999
3,013
3,969
4,953
1,855
1,628
1,462
805
1,922
616
-10,584
-1,985
-10,016
-35,727
-60,957
-38,743
-46,087
-32,961
-24,282
-18,608
10,251
36,205
4,796
-1,587
-1,431
9,609
-1,285
-5,560
-16,498
-4,343
-25,886
-13,949
-13,949-25,886-4,343-16,498-5,560-1,2859,609-1,431-1,5874,79636,20510,251-18,608-24,282-32,961-46,087-38,743-60,957-35,727-10,016-1,985-10,5846161,9228051,4621,6281,8554,9533,9693,0131,999-876-1,4857568851,084-1,200-1,127-495-736-737-69908070-40-10-20,286000000
   Capital Surplus 
0
0
0
0
0
0
0
0
459,392
461,961
465,246
587,128
591,636
596,617
721,722
734,489
747,869
812,294
820,165
829,114
837,850
847,700
856,142
865,834
949,331
958,206
966,534
975,418
1,105,124
1,275,004
1,288,137
1,523,115
1,539,530
1,775,799
1,795,351
1,834,061
2,067,274
2,101,136
2,171,746
2,033,972
2,063,687
2,092,534
2,123,606
2,152,639
2,184,230
2,222,905
2,305,020
2,339,886
2,416,904
0
0
0
0
0
0
0
00000002,416,9042,339,8862,305,0202,222,9052,184,2302,152,6392,123,6062,092,5342,063,6872,033,9722,171,7462,101,1362,067,2741,834,0611,795,3511,775,7991,539,5301,523,1151,288,1371,275,0041,105,124975,418966,534958,206949,331865,834856,142847,700837,850829,114820,165812,294747,869734,489721,722596,617591,636587,128465,246461,961459,39200000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
197,870
325,972
-175,008,692
-166,782,154
-151,437,575
587,128
591,636
596,617
721,722
734,489
747,869
812,294
819,965
829,114
837,850
847,456
855,657
865,958
949,330
958,219
966,503
975,371
1,105,124
1,275,004
1,288,137
1,523,115
1,539,530
1,775,799
1,795,351
1,834,061
2,067,274
2,101,136
2,171,746
2,033,972
2,063,687
2,092,534
2,123,606
2,152,639
2,184,230
2,222,905
2,305,020
2,339,886
2,416,904
2,447,292
2,466,233
2,486,722
2,510,574
2,530,902
2,574,611
2,608,422
2,608,4222,574,6112,530,9022,510,5742,486,7222,466,2332,447,2922,416,9042,339,8862,305,0202,222,9052,184,2302,152,6392,123,6062,092,5342,063,6872,033,9722,171,7462,101,1362,067,2741,834,0611,795,3511,775,7991,539,5301,523,1151,288,1371,275,0041,105,124975,371966,503958,219949,330865,958855,657847,456837,850829,114819,965812,294747,869734,489721,722596,617591,636587,128-151,437,575-166,782,154-175,008,692325,972197,870000000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue806,780
Cost of Revenue-57,398
Gross Profit749,382749,382
 
Operating Income (+$)
Gross Profit749,382
Operating Expense-1,051,952
Operating Income-302,570-302,570
 
Operating Expense (+$)
Research Development534,480
Selling General Administrative300,911
Selling And Marketing Expenses0
Operating Expense1,051,952835,391
 
Net Interest Income (+$)
Interest Income0
Interest Expense-166,993
Other Finance Cost-0
Net Interest Income-166,993
 
Pretax Income (+$)
Operating Income-302,570
Net Interest Income-166,993
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-363,119-242,021
EBIT - interestExpense = -363,119
-363,119
-196,302
Interest Expense166,993
Earnings Before Interest and Taxes (EBIT)-196,126-196,126
Earnings Before Interest and Taxes (EBITDA)-120,463
 
After tax Income (+$)
Income Before Tax-363,119
Tax Provision-176
Net Income From Continuing Ops-363,295-363,295
Net Income-363,295
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses1,109,350
Total Other Income/Expenses Net-60,549166,993
 

Technical Analysis of PTC Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of PTC Therapeutics Inc. The general trend of PTC Therapeutics Inc is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine PTC Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (28.6%) Bearish trend (-28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. PTC Therapeutics Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of PTC Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 50.57 < 52.45 < 52.98.

The bearish price targets are: 35.95 > 35.51 > 34.57.

Know someone who trades $PTCT? Share this with them.👇

PTC Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of PTC Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

PTC Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of PTC Therapeutics Inc. The current macd is -0.11342214.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the PTC Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for PTC Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the PTC Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
PTC Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartPTC Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of PTC Therapeutics Inc. The current adx is 9.69157854.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy PTC Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
PTC Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of PTC Therapeutics Inc. The current sar is 50.27.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
PTC Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of PTC Therapeutics Inc. The current rsi is 52.12. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
PTC Therapeutics Inc Daily Relative Strength Index (RSI) ChartPTC Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of PTC Therapeutics Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the PTC Therapeutics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
PTC Therapeutics Inc Daily Stochastic Oscillator ChartPTC Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of PTC Therapeutics Inc. The current cci is -38.82458515.

PTC Therapeutics Inc Daily Commodity Channel Index (CCI) ChartPTC Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of PTC Therapeutics Inc. The current cmo is 7.11495016.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
PTC Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartPTC Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of PTC Therapeutics Inc. The current willr is -44.35695538.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that PTC Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
PTC Therapeutics Inc Daily Williams %R ChartPTC Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of PTC Therapeutics Inc.

PTC Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of PTC Therapeutics Inc. The current atr is 1.60910292.

PTC Therapeutics Inc Daily Average True Range (ATR) ChartPTC Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of PTC Therapeutics Inc. The current obv is -6,821,449.

PTC Therapeutics Inc Daily On-Balance Volume (OBV) ChartPTC Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of PTC Therapeutics Inc. The current mfi is 33.86.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
PTC Therapeutics Inc Daily Money Flow Index (MFI) ChartPTC Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for PTC Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-18STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-27STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-02-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-03-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-31SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-03WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-04ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-14MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-06BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-07RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-05-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-05-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-05BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-16STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

PTC Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of PTC Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.116
Ma 20Greater thanMa 5049.673
Ma 50Greater thanMa 10048.188
Ma 100Greater thanMa 20049.340
OpenGreater thanClose48.830
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of PTC Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on PTC Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about PTC Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about PTC Therapeutics Inc

I send you an email if I find something interesting about PTC Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about PTC Therapeutics Inc.

Receive notifications about PTC Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.